NASDAQ:KURA

Kura Oncology Stock Forecast, Price & News

$28.59

-0.88 (-2.99 %)

(As of 04/16/2021 04:00 PM ET)

Add

Compare

Today's Range

$27.81

Now: $28.59▼

$29.85

50-Day Range

$24.76

MA: $28.53▼

$31.70

52-Week Range

$9.88

Now: $28.59▼

$43.00

Volume391,723 shs

Average Volume740,641 shs

Market Capitalization$1.89 billion

P/E RatioN/A

Dividend YieldN/A

Beta2.15

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, and other hematologic malignancies. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have dysregulated activity due to mutations or other mechanisms in the mitogen-activated protein kinase pathway; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia protein-protein interaction. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:KURA

Previous Symbol

CUSIPN/A

CIK1422143

Webwww.kuraoncology.com

Phone858-500-8800

Employees88

Year FoundedN/A

Debt

Debt-to-Equity Ratio0.02

Current Ratio15.15

Quick Ratio15.15

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$4.83 per share

Price / Book5.92

Profitability

EPS (Most Recent Fiscal Year)($1.51)

Net Income$-63,140,000.00

Net MarginsN/A

Return on Equity-30.96%

Return on Assets-28.02%

Miscellaneous

Outstanding Shares66,211,000

Market Cap$1.89 billion

Next Earnings Date5/3/2021 (Estimated)

OptionableOptionable

Headlines

Kura Oncology (NASDAQ:KURA) Shares Down 5%
April 13, 2021 | americanbankingnews.com

Zacks: Brokerages Expect Kura Oncology, Inc. (NASDAQ:KURA) to Post -$0.42 Earnings Per Share
April 4, 2021 | americanbankingnews.com

KURA Crosses Above Key Moving Average Level
April 1, 2021 | nasdaq.com

Kura Oncology (NASDAQ:KURA) Shares Gap Up to $26.61
April 1, 2021 | americanbankingnews.com

Is KURA Stock A Buy or Sell?
March 29, 2021 | finance.yahoo.com

Kura Oncology (NASDAQ:KURA) Stock Price Up 5.6%
March 25, 2021 | americanbankingnews.com

Kura Oncology Announces Publication of Tipifarnib Phase 2 Data in Journal of Clinical Oncology
March 22, 2021 | finance.yahoo.com

KURA Makes Notable Cross Below Critical Moving Average
February 25, 2021 | nasdaq.com

RSI Alert: Kura Oncology (KURA) Now Oversold
February 25, 2021 | nasdaq.com

HC Wainwright & Co. Maintains Buy on Kura Oncology, Lowers Price Target to $43
February 24, 2021 | benzinga.com

Kura Oncology Reports Fourth Quarter and Full Year 2020 Financial Results
February 24, 2021 | finance.yahoo.com

Kura Oncology to Participate in Four Upcoming Investor Conferences
February 18, 2021 | finance.yahoo.com

Kura Oncology to Report Fourth Quarter and Full Year 2020 Financial Results
February 17, 2021 | finance.yahoo.com

What Is The Ownership Structure Like For Kura Oncology, Inc. (NASDAQ:KURA)?
January 25, 2021 | finance.yahoo.com

First Week of KURA March 19th Options Trading
January 20, 2021 | nasdaq.com

OncoDNA Announces Expansion of Its Services Into the United States
January 7, 2021 | benzinga.com

Kura Oncology to Participate in H.C. Wainwright BioConnect 2021 Conference
January 7, 2021 | finance.yahoo.com

KURA Jul 2021 20.000 put
January 4, 2021 | ca.finance.yahoo.com

KURA Jul 2021 40.000 put
January 4, 2021 | ca.finance.yahoo.com

Is KURA A Good Stock To Buy According To Hedge Funds?
December 22, 2020 | finance.yahoo.com

See More Headlines

MarketRank^™

Overall MarketRank^™

1.56 out of 5 stars

Medical Sector

432nd out of 2,025 stocks

Pharmaceutical Preparations Industry

211th out of 772 stocks

3.5 Analyst's Opinion

Consensus Rating
Kura Oncology has received a consensus rating of Buy. The company's average rating score is 2.91, and is based on 10 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $39.55, Kura Oncology has a forecasted upside of 38.3% from its current price of $28.59.
Amount of Analyst Coverage
Kura Oncology has only been the subject of 2 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
Kura Oncology has received 365 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Kura Oncology has received 315 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Kura Oncology has received 53.68% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Kura Oncology and other stocks. Vote “Outperform” if you believe KURA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe KURA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Kura Oncology does not currently pay a dividend.
Dividend Growth
Kura Oncology does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Kura Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $183,938.00 in company stock.
Percentage Held by Insiders
Only 11.00% of the stock of Kura Oncology is held by insiders.
Percentage Held by Institutions
94.72% of the stock of Kura Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Kura Oncology are expected to decrease in the coming year, from ($1.69) to ($2.02) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Kura Oncology is -17.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Kura Oncology is -17.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Kura Oncology has a P/B Ratio of 5.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$28.59

-0.88 (-2.99 %)

(As of 04/16/2021 04:00 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive KURA News and Ratings via Email

Sign-up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter.

Kura Oncology (NASDAQ:KURA) Frequently Asked Questions

Is Kura Oncology a buy right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last twelve months. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Kura Oncology stock.
View analyst ratings for Kura Oncology or view top-rated stocks.

What stocks does MarketBeat like better than Kura Oncology?

Wall Street analysts have given Kura Oncology a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Kura Oncology wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Kura Oncology's next earnings date?

Kura Oncology is scheduled to release its next quarterly earnings announcement on Monday, May 3rd 2021.
View our earnings forecast for Kura Oncology.

How were Kura Oncology's earnings last quarter?

Kura Oncology, Inc. (NASDAQ:KURA) released its quarterly earnings data on Wednesday, February, 24th. The company reported ($0.45) EPS for the quarter, meeting the consensus estimate of ($0.45).
View Kura Oncology's earnings history.

How has Kura Oncology's stock price been impacted by COVID-19 (Coronavirus)?

Kura Oncology's stock was trading at $9.65 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, KURA shares have increased by 196.3% and is now trading at $28.59.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for KURA?

11 brokers have issued 12-month price objectives for Kura Oncology's shares. Their forecasts range from $24.00 to $56.00. On average, they expect Kura Oncology's share price to reach $39.55 in the next twelve months. This suggests a possible upside of 38.3% from the stock's current price.
View analysts' price targets for Kura Oncology or view top-rated stocks among Wall Street analysts.

Who are Kura Oncology's key executives?

Kura Oncology's management team includes the following people:

Dr. Troy Edward Wilson, Chairman, CEO & Pres (Age 52, Pay $908.26k)
Dr. Marc Grasso, CFO & Chief Bus. Officer (Age 48, Pay $630.86k)
Ms. Kathleen Ford, Chief Operating Officer (Age 74, Pay $492.28k)
Mr. James E. Basta J.D., Esq., Chief Legal Officer, Chief Compliance Officer & Corp. Sec. (Age 55, Pay $168.94k)
Mr. Pete De Spain, VP of Investor Relations & Corp. Communications
Dr. Blake Tomkinson M.B.A., Ph.D., Head of Portfolio Strategy & Program Management
Ms. Kirsten Flowers, Chief Commercial Officer (Age 46)
Dr. Roger Bakale Ph.D., VP and Head of CMC, Clinical & Commercial Manufacturing
Dr. Stephen Dale M.D., Chief Medical Officer
Dr. Nic G. Scalfarotto, Sr. VP of Regulatory Affairs

Who are some of Kura Oncology's key competitors?

Some companies that are related to Kura Oncology include Ultragenyx Pharmaceutical (RARE), Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals (GWPH), Evotec (EVTCY), Ascendis Pharma A/S (ASND), TG Therapeutics (TGTX), Ionis Pharmaceuticals (IONS), Sarepta Therapeutics (SRPT), Perrigo (PRGO), Allakos (ALLK), Blueprint Medicines (BPMC), Schrödinger (SDGR), Galapagos (GLPG), Biohaven Pharmaceutical (BHVN) and Sage Therapeutics (SAGE).
View all of KURA's competitors.

What other stocks do shareholders of Kura Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD).

What is Kura Oncology's stock symbol?

Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."

Who are Kura Oncology's major shareholders?

Kura Oncology's stock is owned by many different institutional and retail investors. Top institutional shareholders include Pacer Advisors Inc. (0.00%). Company insiders that own Kura Oncology stock include Antonio Gualberto, Kathleen Ford, Marc Grasso and Troy Edward Wilson.
View institutional ownership trends for Kura Oncology.

Which major investors are selling Kura Oncology stock?

KURA stock was sold by a variety of institutional investors in the last quarter, including Pacer Advisors Inc.. Company insiders that have sold Kura Oncology company stock in the last year include Kathleen Ford, Marc Grasso, and Troy Edward Wilson.
View insider buying and selling activity for Kura Oncology or view top insider-selling stocks.

How do I buy shares of Kura Oncology?

Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kura Oncology's stock price today?

One share of KURA stock can currently be purchased for approximately $28.59.

How much money does Kura Oncology make?

Kura Oncology has a market capitalization of $1.89 billion. The company earns $-63,140,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis.

How many employees does Kura Oncology have?

Kura Oncology employs 88 workers across the globe.

What is Kura Oncology's official website?

The official website for Kura Oncology is www.kuraoncology.com.

Where are Kura Oncology's headquarters?

Kura Oncology is headquartered at 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130.

How can I contact Kura Oncology?

Kura Oncology's mailing address is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. The company can be reached via phone at 858-500-8800 or via email at [email protected]

This page was last updated on 4/16/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here